AVIEW LCS vs EchoNext

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

AVIEW LCS

by Coreline Soft Co.

EchoNext

by Pathway Labs

AI Verdict

AVIEW LCS and EchoNext both offer AI-powered cardiac assessments, making them adjacent in the cardiology AI space. AVIEW LCS focuses on comprehensive cardiopulmonary analysis from CT scans, including coronary artery calcification and lung nodule detection, while EchoNext specializes in detecting hidden structural heart disease using standard ECGs. The choice between them depends on whether the diagnostic need is for CT-based cardiopulmonary screening or ECG-based structural heart disease detection.

Choose AVIEW LCS if…

Choose AVIEW LCS if your primary need is comprehensive, AI-powered analysis of low-dose CT scans for lung cancer screening, COPD, and coronary artery calcification. This tool excels at automated lung nodule detection, classification (e.g., Lung-RADS), volume quantification, and comparison in follow-up scans, providing a holistic cardiopulmonary assessment from a single imaging study.

View AVIEW LCS →

Choose EchoNext if…

Choose EchoNext if your focus is on early, non-invasive detection of hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension, using standard ECGs. This AI tool is ideal for broad screening initiatives, particularly in settings where access to echocardiography may be limited, to identify high-risk patients who warrant further cardiac evaluation.

View EchoNext →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	AVIEW LCS	EchoNext
Pricing	Contact for pricing	Starts at $600/month
Deployment	Cloud-based, Hybrid solution, Locally on dedicated hardware, Locally virtualized (virtual machine, Docker)	Available through the OpenEvidence clinical decision support platform.
BAA Available	Unknown	Yes AI-estimated
FDA Status	1 AI-estimated	Yes AI-estimated
HIPAA	Unknown	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

AVIEW LCS

AVIEW LCS emphasizes a user-friendly viewer with advanced 3D rendering of the patient's lung, which can make complex findings more intuitive for both medical professionals and patients. It also highlights automated report generation and Lung-RADS classification, which can streamline workflows and reduce manual tasks.

Clinical Value

EchoNext

EchoNext has demonstrated superior diagnostic accuracy compared to expert cardiologists in multiple validation studies, even when cardiologists were assisted by AI. It has also been credited with detecting previously undiagnosed heart failure that led to a heart transplant, highlighting its potential for earlier, life-saving interventions.

Pricing & Value

EchoNext

EchoNext offers transparent tiered pricing starting at $600/month, with details on different plans and potential discounts. AVIEW LCS, on the other hand, requires contacting them for pricing, which offers less immediate transparency for potential buyers. EchoNext's clear pricing structure allows for easier budget planning and comparison.

Enterprise Readiness

AVIEW LCS

AVIEW LCS offers multiple deployment options including cloud-based, hybrid, and local installations, providing flexibility for various enterprise IT infrastructures. It also boasts integration with PACS/RIS and third-party platforms, and has processed over 2.5 million cases across 19 countries, demonstrating its scalability and proven adoption in diverse healthcare ecosystems.

Innovation

EchoNext

EchoNext is highlighted as the world's first FDA-cleared AI tool for detecting hidden structural heart disease from standard ECGs, a significant breakthrough in non-invasive cardiac screening. This represents a novel application of AI to a widely available and inexpensive diagnostic test, potentially transforming early detection of serious heart conditions.

Support & Docs

Tie

Both tools are FDA-cleared and have published clinical validation studies, indicating a baseline of regulatory and scientific documentation. However, specific details regarding ongoing customer support, training programs, or the breadth and accessibility of user documentation are not extensively provided for either tool in the available information.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	AVIEW LCS	EchoNext
Tool Name	AVIEW LCS	EchoNext
Company	Coreline Soft Co.	Pathway Labs
Tagline	AI-Powered Lung Cancer Screening & Cardiopulmonary Assessment	How's your heart?
Categories	Cardiology AI, Oncology AI, Radiology & Imaging AI	Cardiology AI, Clinical Decision Support & Reference, Lab & Diagnostics
Key Features	Automated lung nodule detection and analysis, Lung-RADS classification and reporting, Nodule volume quantification and 3D segmentation, Emphysema quantification (LAA index), Coronary Artery Calcification (CAC) scoring (Agatston, volume, mass), Automated comparison of nodules in follow-up CT scans, Comprehensive, automated report generation, Integration with PACS/RIS and third-party platforms	AI-powered ECG analysis, Detection of hidden structural heart disease, Identifies heart failure risk, Screens for valve disease, Detects pulmonary hypertension indicators, Utilizes standard 12-lead ECGs, FDA-cleared technology, Non-invasive diagnostic support

Videos

Demos, reviews, and walkthroughs featuring AVIEW LCS and EchoNext.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How deeply do these tools integrate with existing EHR and PACS/RIS systems, and what is the typical implementation timeline?

AVIEW LCS supports standard DICOM connectivity and integrates with existing PACS and RIS environments, and can operate as a standalone workstation or be embedded within third-party platforms. Implementation for AVIEW LCS can typically be completed within weeks for institutions with standard PACS/DICOM environments. EchoNext is available through the OpenEvidence clinical decision support platform, which serves over 500,000 physicians nationwide, integrating its screening output into tools physicians already use at the point of care.

What is the reported accuracy and sensitivity of each tool in detecting the specified conditions?

AVIEW LCS reports a sensitivity of 97% and specificity of 76% for lung nodule detection. It has also shown a lower likelihood of misidentifying nodules larger than 100 mmu00b3 compared with human radiologists. EchoNext accurately identified 77% of structural heart problems in a head-to-head comparison with 13 cardiologists on 3,200 ECGs, whereas cardiologists achieved 64% accuracy. The deep learning model for EchoNext was trained on over 700,000 ECG-echocardiogram pairs and achieved an AUROC of 85% in internal tests and 78-80% in external validation.

What is the expected learning curve for physicians and radiologists to effectively utilize these AI tools in their daily workflow?

AVIEW LCS is designed to reduce radiologist workload by an estimated 77.4% to 86.7% and interpretation time by 70%, suggesting a streamlined workflow once integrated. It provides clear reports with 2D and 3D visualizations to aid understanding. EchoNext is integrated into the OpenEvidence platform, aiming to make a breakthrough in heart disease detection available within existing physician workflows, which could imply a lower learning curve as it leverages familiar interfaces.

Beyond HIPAA, what additional security measures or certifications do these tools offer to protect patient data?

AVIEW LCS holds CE marking under the EU Medical Device Regulation (MDR) and full GDPR compliance, in addition to HIPAA. Coreline Soft emphasizes that AVIEW CAD meets the highest international security standards. While specific additional certifications beyond HIPAA are not detailed for EchoNext, generally, AI security for sensitive data involves measures like least-privilege access, data classification, and continuous posture monitoring to address risks beyond HIPAA's scope.

Are there customer references or case studies available that demonstrate the real-world impact and time-to-value of these tools in clinical settings?

AVIEW LCS has been deployed at Temple Health, where it has streamlined clinical workflows and delivered measurable improvements in care and ROI. SOL Radiology also reported significant gains in diagnostic efficiency and consistency within one week of AVIEW LCS implementation. EchoNext has a published case in Nature Medicine where it helped guide the care of a patient who ultimately underwent a heart transplant, demonstrating its clinical impact. Pathway Labs is also collaborating with OpenEvidence to expand access to EchoNext's screening tool.

What audit-trail features are available to track AI-assisted diagnoses and physician interactions with the tools?

AVIEW LCS generates comprehensive, automated reports, including Lung-RADS classification and reporting, nodule volume quantification, and automated comparison of nodules in follow-up CT scans. These outputs support structured reporting workflows and can be incorporated into institutional reporting templates. While specific audit-trail features for EchoNext are not detailed, AI security best practices generally include continuous monitoring and logging of access and activity to align with audit requirements.

How do these tools support multi-site rollouts, and what considerations should be made for consistent implementation across different locations?

AVIEW LCS supports deployment configurations that enable oversight across multiple sites, applying the same detection algorithms and measurement protocols to eliminate variability. This provides a standardized quality baseline for hospital groups and radiology networks. Coreline Soft offers flexible licensing models tailored to the scale and structure of screening programs, whether single-site, multi-site, or network-wide. EchoNext, through its partnership with OpenEvidence, aims for broad access, from major hospitals to community practices, suggesting a design for scalable deployment across various healthcare settings.